The global neurological device market was valued at $12.2 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.1%, reaching $16.1 billion by 2032.
This report covers cerebrospinal fluid (CSF) management devices, detachable coils, liquid embolics, neurovascular catheters, neurovascular guidewires, neurovascular stents, balloon occlusion devices, aneurysm clips, neurovascular thrombus management devices, neuromodulation devices, intrathecal pumps, stereotactic devices, and ultrasonic aspirators. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is shaped by an aging global population that is increasing the incidence of conditions such as hydrocephalus and traumatic brain injury, and by the growing adoption of minimally invasive neurovascular intervention across endovascular and interventional settings. Emerging technologies including artificial intelligence, augmented reality, and cloud-based neuroimaging platforms are improving diagnostic precision, intraoperative navigation, and cross-facility care coordination, supporting broader adoption of advanced neurological procedures.
Key restraints include complications and revision burdens associated with CSF shunt systems and a historically slow pace of product innovation in the CSF management segment, where hospital budget constraints and limited commercial incentive have maintained a negative feedback loop between manufacturer investment and institutional adoption of new designs.
Emerging technologies are increasingly shaping market development across multiple device categories. Artificial intelligence and machine learning are enhancing diagnostic precision and procedural efficiency through advanced imaging analysis and predictive modeling, enabling earlier detection of neurological conditions and supporting more personalized treatment pathways. Augmented and virtual reality are improving neurosurgical training and intraoperative navigation by providing real-time three-dimensional visualization of patient anatomy. Cloud-based neuroimaging platforms are streamlining data management and enabling remote consultation and coordinated care, particularly when integrated with AI-driven analytics.
An aging global population is the primary demographic driver across multiple device categories. Hydrocephalus affects the elderly disproportionately, and as this demographic grows, demand for shunts and external drainage systems will rise. The annual number of traumatic brain injury cases is also increasing, supporting procedural volume growth across neurovascular and neurosurgical device categories. Chronic neurological conditions such as stroke, intracranial aneurysm, and movement disorders that benefit from neuromodulation therapy are similarly more prevalent in older populations, creating a durable demand base across several market segments.
The market for minimally invasive neurovascular procedures continues to grow as interventional platforms become more capable and clinical evidence accumulates. Endovascular approaches to aneurysm treatment, stroke intervention, and embolization are displacing open surgical techniques, driving demand for detachable coils, liquid embolics, flow diversion stents, stent retrievers, and aspiration catheters. Neuromodulation is also expanding through spinal cord stimulation and deep brain stimulation platforms that now offer personalized therapy programming and MRI compatibility, broadening the eligible patient population and supporting sustained segment growth.
Stryker holds the second-leading position in 2025, driven by strength in neurovascular and stroke-related interventions. The company demonstrates leadership in neurovascular guidewires and ultrasonic aspiration while also maintaining a competitive position in detachable coils, balloon occlusion, neurovascular stents, and thrombus management. Stryker's portfolio is focused on interventional solutions, positioning it to capitalize on the growing demand for minimally invasive neurovascular procedures. This targeted strength across key endovascular segments supports its standing as a major global competitor.
Boston Scientific ranks as the third-leading competitor in 2025, with its position largely supported by strength in neuromodulation. The company has advanced beyond its earlier Precision systems and expanded its spinal cord stimulation portfolio with platforms such as WaveWriter Alpha and Spectra WaveWriter, which offer multi-waveform capabilities and enhanced programming for personalized therapy. Ongoing enhancements including MRI compatibility and integrated digital features strengthen its competitive position and allow it to maintain a leading standing in the overall market despite narrower segment diversification relative to the two market leaders.
73 charts and 532 figures illustrating market segmentation and performance metrics across all 13 device categories.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers cerebrospinal fluid (CSF) management devices, detachable coils, liquid embolics, neurovascular catheters, neurovascular guidewires, neurovascular stents, balloon occlusion devices, aneurysm clips, neurovascular thrombus management devices, neuromodulation devices, intrathecal pumps, stereotactic devices, and ultrasonic aspirators. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is shaped by an aging global population that is increasing the incidence of conditions such as hydrocephalus and traumatic brain injury, and by the growing adoption of minimally invasive neurovascular intervention across endovascular and interventional settings. Emerging technologies including artificial intelligence, augmented reality, and cloud-based neuroimaging platforms are improving diagnostic precision, intraoperative navigation, and cross-facility care coordination, supporting broader adoption of advanced neurological procedures.
Key restraints include complications and revision burdens associated with CSF shunt systems and a historically slow pace of product innovation in the CSF management segment, where hospital budget constraints and limited commercial incentive have maintained a negative feedback loop between manufacturer investment and institutional adoption of new designs.
Market Overview
The global neurological device market is one of the largest and most diverse segments in medical technology, spanning cerebrospinal fluid management, endovascular neurovascular intervention, neuromodulation, and neurosurgical instrumentation. The market encompasses both high-volume consumable categories such as catheters and guidewires and high-value capital and implantable platforms such as deep brain stimulation systems and intrathecal pumps. This breadth means that growth drivers and commercial dynamics vary meaningfully across segments, with demographic trends, technology adoption, and reimbursement policy each playing different roles depending on the indication.Emerging technologies are increasingly shaping market development across multiple device categories. Artificial intelligence and machine learning are enhancing diagnostic precision and procedural efficiency through advanced imaging analysis and predictive modeling, enabling earlier detection of neurological conditions and supporting more personalized treatment pathways. Augmented and virtual reality are improving neurosurgical training and intraoperative navigation by providing real-time three-dimensional visualization of patient anatomy. Cloud-based neuroimaging platforms are streamlining data management and enabling remote consultation and coordinated care, particularly when integrated with AI-driven analytics.
An aging global population is the primary demographic driver across multiple device categories. Hydrocephalus affects the elderly disproportionately, and as this demographic grows, demand for shunts and external drainage systems will rise. The annual number of traumatic brain injury cases is also increasing, supporting procedural volume growth across neurovascular and neurosurgical device categories. Chronic neurological conditions such as stroke, intracranial aneurysm, and movement disorders that benefit from neuromodulation therapy are similarly more prevalent in older populations, creating a durable demand base across several market segments.
The market for minimally invasive neurovascular procedures continues to grow as interventional platforms become more capable and clinical evidence accumulates. Endovascular approaches to aneurysm treatment, stroke intervention, and embolization are displacing open surgical techniques, driving demand for detachable coils, liquid embolics, flow diversion stents, stent retrievers, and aspiration catheters. Neuromodulation is also expanding through spinal cord stimulation and deep brain stimulation platforms that now offer personalized therapy programming and MRI compatibility, broadening the eligible patient population and supporting sustained segment growth.
Market Drivers
Demographic Factors
Hydrocephalus affects the elderly more frequently than other patient groups, and as the global population ages the incidence of this condition will rise, driving increased demand for shunts and CSF drainage products across both implantable and external drainage categories. These demographic dynamics are also expanding the external drainage system market as more patients develop conditions requiring active cerebrospinal fluid management. The number of traumatic brain injury cases occurring annually is increasing, further contributing to procedural volume growth across neurovascular and neurosurgical device categories. This aging and injury trend creates a sustained demand base across CSF management, thrombus management, neuromodulation, and related segments, supporting market growth that is largely independent of procedural technology adoption rates.Advancing Technology
Emerging shunt technologies are making CSF management devices a more attractive treatment option for physicians, while advances in intracranial pressure monitoring are improving hydrocephalus diagnosis rates and expanding the identified patient population. Antimicrobial catheters represent the next significant innovation in the CSF shunt market, with antimicrobial coatings on distal catheter ends designed to reduce infection rates and the associated revision burden. These advances are expected to support higher ASPs in the CSF management segment and drive market value growth. More broadly, the integration of AI-driven imaging analysis, AR-assisted surgical navigation, and cloud-based neuroimaging is improving the precision and efficiency of neurological procedures across multiple indications, accelerating adoption of advanced device platforms throughout the market.Market Limiters
Shunt Efficacy and Revision Burden
Hydrocephalus shunts are effective when functioning correctly, but they are subject to multiple complications that frequently require revision surgery. Shunts can become blocked, infected, or disconnected, causing symptoms to re-emerge. These symptoms range from mild presentations such as headaches, nausea, and vomiting to more serious complications including seizures and cognitive dysfunction. Most patients with hydrocephalus will require at least one revision procedure during their lifetime, exposing them to repeated surgical risk and placing a sustained procedural burden on the healthcare system that reflects complications rather than new indications. Patients with magnetic components in their shunts must also follow highly specific safety guidelines for MRI procedures, adding clinical management complexity and limiting diagnostic flexibility.Lack of Innovation in CSF Management
Healthcare centers operate with limited budgets and are often hesitant to adopt more expensive, innovative products when existing options are considered clinically adequate. Since the hydrocephalus shunt was first introduced in the 1960s, the core design has changed very little beyond the introduction of adjustable pressure valves. This creates a negative feedback loop in which manufacturers are unlikely to invest in significantly improved products when institutional purchasing behavior does not reward innovation, and providers see little incentive to advocate for change when current products remain functional. Government initiatives, including potential policy spillover effects from the European Union, have the potential to disrupt this dynamic and encourage renewed investment in CSF management design, but meaningful innovation in this segment remains limited over the near-term forecast period.Market Coverage and Data Scope
- Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, disruptive technologies, and disease overviews shaping demand across neurological indications.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with neurology and neurosurgery industry leaders and clinicians, government and physician data, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals, neurosurgery centers, interventional radiology suites, and ambulatory specialty clinics.
Markets Covered and Segmentation
Cerebrospinal Fluid (CSF) Management Market
- Device type: CSF Shunt and CSF External Drainage System
Detachable Coil Market
- Material type: Bare Platinum and Coated
Liquid Embolic Market
Neurovascular Guidewire Market
Neurovascular Catheter Market
- Device type: Over-the-Wire Microcatheter, Flow-Directed Microcatheter, and Neurovascular Guiding Catheter
Neurovascular Stent Market
- Device type: Traditional Neurovascular Stent, Flow Diversion Stent, and Intrasaccular Stent
Balloon Occlusion Device Market
Aneurysm Clip Market
- Material type: Titanium and Cobalt Alloy
- Device modality: Temporary and Permanent
Neurovascular Thrombus Management Market
- Device type: Stent Retriever, Aspiration Catheter, and Aspiration Pump Canister
Neuromodulation Device Market
- Device type: Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, and Gastric Electric Stimulation
Intrathecal Pump Market
Stereotactic Device Market
- Device type: Frame-Based and Frameless
Ultrasonic Aspirator Market
- Device type: Capital Equipment, Disposable Probe Tip, Disposable Tubing, Handpiece, and Accessories
Competitive Analysis
Medtronic holds the leading position in the global neurological device market in 2025, supported by a broad and well-diversified portfolio across multiple segments. The company demonstrates particularly strong dominance in cerebrospinal fluid management, liquid embolics, intrathecal pumps, and stereotactic devices, while also maintaining a leading presence in neuromodulation and neurovascular stents. Medtronic also competes effectively in thrombus management and detachable coils, reinforcing its position across both therapeutic and interventional applications. This extensive segment coverage, combined with the ability to hold strong positions across several high-value device categories, enables Medtronic to sustain its global market leadership.Stryker holds the second-leading position in 2025, driven by strength in neurovascular and stroke-related interventions. The company demonstrates leadership in neurovascular guidewires and ultrasonic aspiration while also maintaining a competitive position in detachable coils, balloon occlusion, neurovascular stents, and thrombus management. Stryker's portfolio is focused on interventional solutions, positioning it to capitalize on the growing demand for minimally invasive neurovascular procedures. This targeted strength across key endovascular segments supports its standing as a major global competitor.
Boston Scientific ranks as the third-leading competitor in 2025, with its position largely supported by strength in neuromodulation. The company has advanced beyond its earlier Precision systems and expanded its spinal cord stimulation portfolio with platforms such as WaveWriter Alpha and Spectra WaveWriter, which offer multi-waveform capabilities and enhanced programming for personalized therapy. Ongoing enhancements including MRI compatibility and integrated digital features strengthen its competitive position and allow it to maintain a leading standing in the overall market despite narrower segment diversification relative to the two market leaders.
Technology and Practice Trends
- AI and machine learning in neurological care: AI-driven imaging analysis and predictive modeling are improving diagnostic precision and enabling earlier detection of neurological conditions, supporting more personalized and timely treatment decisions.
- Augmented and virtual reality for training and navigation: AR and VR tools are improving neurosurgical training and intraoperative navigation through real-time three-dimensional visualization of patient anatomy, increasing procedural accuracy.
- Cloud-based neuroimaging: Cloud platforms are streamlining neuroimaging data management and enabling faster diagnoses, remote consultations, and more coordinated care across facilities when combined with AI-driven analytics.
- Antimicrobial catheter innovation: Antimicrobial coatings on CSF shunt catheter ends represent the next major product advancement in the CSF management segment, targeting infection reduction and the associated revision burden.
- Minimally invasive neurovascular procedures: Endovascular approaches to aneurysm treatment, stroke intervention, and embolization continue to displace open surgery, driving demand across coils, flow diversion stents, stent retrievers, and aspiration catheters.
- Advanced neuromodulation platforms: Multi-waveform spinal cord stimulation and MRI-compatible deep brain stimulation systems are expanding the eligible patient population for implantable neuromodulation therapy.
- Frameless stereotactic systems: Frameless approaches are gaining adoption over traditional frame-based systems for their procedural efficiency and improved patient comfort in stereotactic neurosurgery applications.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
783 pages of detailed narrative analysis, tables, and figures.73 charts and 532 figures illustrating market segmentation and performance metrics across all 13 device categories.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the largest and fastest-growing opportunities within the global neurological device market through 2032, across all 13 device categories?
- How are artificial intelligence, machine learning, augmented reality, and cloud-based neuroimaging transforming neurological diagnosis, surgical navigation, and care coordination?
- What demographic trends are driving demand across CSF management, thrombus management, and neuromodulation, and how are these projected to evolve through the forecast period?
- How are antimicrobial catheter innovations and advances in intracranial pressure monitoring expected to affect ASPs and market value growth in the CSF management segment?
- Which endovascular device categories are gaining share as minimally invasive approaches displace open neurosurgical techniques for aneurysm and stroke intervention?
- Which companies lead each segment and what are their portfolio strengths, innovation strategies, and recent acquisition activity?
- How do shunt complication rates, revision burdens, and MRI compatibility constraints limit the commercial opportunity in CSF management?
- What are the key risks to growth, including limited design innovation in mature device categories, hospital budget constraints, and reimbursement variability across global markets?
Table of Contents
Executive Summary
Research Methodology
Global Neurological Device Market Overview
Cerebrospinal Fluid Management Market
Detachable Coil Market
Liquid Embolic Market
Neurovascular Guidewire Market
Neurovascular Catheter Market
Neurovascular Stent Market
Balloon Occlusion Market
Aneurysm Clip Market
Neurovascular Thrombus Management Market
Neuromodulation Device Market
Intrathecal Pump Market
Stereotactic Device Market
Ultrasonic Aspirator Market
List of Charts
List of Figures
